Payment overview · 2025
General Payments
$3,071.20
129 reported records · 19 companies
Healthcare provider profile · identity verified
Kamran Matin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · TORRANCE, CA · NPI 1225074982
Verified facts
What the public records show
CMS Open Payments records show Kamran Matin, M.D. received $3,071.20 in general payments during 2025 across 129 reported records.
Gilead Sciences, Inc. accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Brilinta, Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Verquvo.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Eliquis by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Biktarvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $635.51 | 20.7% | 20 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $385.60 | 12.6% | 15 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $313.12 | 10.2% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $311.32 | 10.1% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $209.92 | 6.8% | 11 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $208.66 | 6.8% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $161.35 | 5.2% | 10 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $154.53 | 5.0% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $139.09 | 4.5% | 5 | 2025 |
| Lexicon Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.59 | 4.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $90.67 | 3.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.96 | 2.3% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $71.30 | 2.3% | 4 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $57.22 | 1.9% | 5 | 2025 |
| AltaThera Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $32.58 | 1.1% | 1 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.55 | 0.9% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $25.97 | 0.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.78 | 0.8% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $24.48 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,071.20 | 129 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $312.18 | 14 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $243.53 | 12 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $194.71 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $165.44 | 6 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $154.53 | 6 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $118.53 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $114.16 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $105.48 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $105.48 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $102.82 | 7 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $94.50 | 8 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $91.82 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $90.67 | 3 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $84.50 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $71.96 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $71.30 | 4 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $61.86 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.53 | 3 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $57.22 | 5 | 2025 |
Source payment records
|
|||||
| Sotalol Hydrochloride Normalized: sotalol hydrochloride |
Drug | AltaThera Pharmaceuticals LLC | $32.58 | 1 | 2025 |
Source payment records
|
|||||
| TRYNGOLZA Normalized: tryngolza |
Drug | Ionis Pharmaceuticals, Inc. | $28.55 | 1 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $26.59 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $25.97 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $22.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| BRILINTA brilinta |
2025 | Brilinta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 158 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 135 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 72 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 115 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
135 | 42 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
158 | 36 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
135 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
72 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 411 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 386 | 133 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 58 |
| Eliquis | Apixaban | 158 | 36 |
| Jardiance | Empagliflozin | 135 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 45 |
| Ozempic | Semaglutide | 115 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 110 | 31 |
| Carvedilol | Carvedilol | 101 | 30 |
| Metformin Hcl | Metformin Hcl | 82 | 32 |
| Irbesartan | Irbesartan | 77 | 27 |
| Valsartan | Valsartan | 75 | 27 |
| Mounjaro | Tirzepatide | 72 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 65 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 22 |
| Alprazolam | Alprazolam | 59 | 16 |
| Lisinopril | Lisinopril | 54 | 21 |
| Spironolactone | Spironolactone | 54 | 23 |
| Trulicity | Dulaglutide | 50 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 16 |
| Gabapentin | Gabapentin | 45 | 12 |
| Clonidine Hcl | Clonidine Hcl | 44 | 18 |
| Entresto | Sacubitril/Valsartan | 44 | 11 |
| Allopurinol | Allopurinol | 39 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 37 | suppressed |
| Furosemide | Furosemide | 36 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 15 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 32 | 15 |
| Edarbi | Azilsartan Medoxomil | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | 12 |
| Lorazepam | Lorazepam | 29 | 11 |
| Losartan Potassium | Losartan Potassium | 29 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | 13 |
| Atenolol | Atenolol | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 24 | 12 |
| Temazepam | Temazepam | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Verquvo | Vericiguat | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Livalo | Pitavastatin Calcium | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Serostim | Somatropin | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 12 | 11 |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Inpefa | Sotagliflozin | 12 | suppressed |
| Singulair | Montelukast Sodium | 12 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,071.20 · 129 records | Gilead Sciences, Inc. | APRETUDE, AREXVY, BRILINTA, Biktarvy, CAMZYOS, DOVATO, ELIQUIS, FARXIGA, FUROSCIX, JARDIANCE, Kerendia, LEQVIO, LifeVest, MOUNJARO, OPSYNVI, Ozempic, REPATHA, RUKOBIA, SHINGRIX, Sotalol Hydrochloride, TRYNGOLZA, UPTRAVI, VERQUVO, WAINUA, Wegovy, YUPELRI, Yeztugo, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error